BEST POSSIBLE COPY

! FINAL DEMOL Wednesday, 29th October 1997 Page 1 of 1

SC-58635 PHENYTOIN PHARMACOKINETIC STUDY IN HEALTHY SUBJECTS
N49-97-02-050

APPENDIX 3.5
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	AGE (yr)	DATE OF BIRTH	DATE OF VISIT	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US0001							
0001	35		23JAN1997	F	CAUCASIAN		
0002	25		23JAN1997	M	CAUCASIAN		
0003	31		23JAN1997	F	CAUCASIAN		
0004	24		23JAN1997	M	CAUCASIAN		
0005	22		23JAN1997	M	CAUCASIAN		
0006	26		23JAN1997	F	HISPANIC		
0007	22		23JAN1997	M	CAUCASIAN		
0008	24		23JAN1997	M	CAUCASIAN		
0009	2[illegible]		23JAN1997	M	CAUCASIAN		
0010	25		23JAN1997	M	CAUCASIAN		
0011	41		23JAN1997	M	CAUCASIAN		
0012	22		23JAN1997	F	CAUCASIAN		
0013	47		23JAN1997	F	CAUCASIAN		
0014	50		23JAN1997	M	BLACK		
0015	37		23JAN1997	M	AFRICAN AMERICAN		
0016	32		23JAN1997	F	CAUCASIAN		
9004	25		30JAN1997	F	CAUCASIAN		

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

159

BEST POSSIBLE COPY

SC-58635 PHENYTOIN PHARMACOKINETIC STUDY IN HEALTHY SUBJECTS
N49-97-02-050

APPENDIX 3.9
LIST OF PHENYTOIN INDIVIDUAL CALCULATED PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	VISIT	TREATMENT	AUC (0-24) (mcg/mL)*hr	Cmax (mcg/mL)	Tmax (hr)
<<< INVESTIGATIONAL UNIT CODE: US0001					
0001	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
0002	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0003	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0004	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
0005	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0006	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0007	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
0008	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
0009	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			

Note: Subject 0004 was withdrawn fro... ...e study due to protocol entry violations.

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

! FINAL PLSM_PK Wednesday, 29th October 1997 Page 2 of 2

SC-58635 PHENYTOIN PHARMACOKINETIC STUDY IN HEALTHY SUBJECTS
N49-97-02-050

APPENDIX 3.9
LIST OF PHENYTOIN INDIVIDUAL CALCULATED PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	VISIT	TREATMENT	AUC (0-24) (mcg/mL)*hr	Cmax (mcg/mL)	Tmax (hr)
<<< INVESTIGATIONAL UNIT CODE: US0001					
0010	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
0011	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0012	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0013	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0014	DAY 0				
	DAY 7	SC-58635 200MG BID			
	DAY 14	PLACEBO			
0015	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
0016	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			
9004	DAY 0				
	DAY 7	PLACEBO			
	DAY 14	SC-58635 200MG BID			

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.

Table 1: Sample Size by Study and Dose

N	OA STUDY Protocol N49-96-02-020			RA STUDY Protocol N49-96-02-023			Total
	50 mg	100 mg	200 mg	100 mg	200 mg	400 mg	
Patients.	29	21	28	13	10	9	110
Obs.	84	62	84	39	30	27	326

Table 2: Descriptive Statistics (N=110) for Continuous Covariates

Covariate	Mean + SD	Median	Min-Max
Age (yrs)	58.2 ± 10.8	59	
Weight (kg)	83.2 ± 20.3	81.4	
Height (cm)	166 ± 11	165	
BSA (m^2)	1.90 ± 0.26	1.91	
Meal time (hr)	0.711 ± 3.03	0.0	
Serum Creatinine (mg/dl)	0.800 ± 0.235	0.7	
Creatinine Clearance (ml/min)	112 ± 39	108	
SGOT (units/l)	21.5 ± 6.0	20	
SGPT (units/l)	22.0 ± 10.3	20	
Compliance Rate	0.930 ± 0.049	0.933	
Days on Study Drug	76.7 ± 19.6	85	

Table 3: Descriptive Statistics (N=110) for Discrete Covariates

Covariate	Frequency	Percent
Gender		
Female	77	70.0
Male	33	30.0
Race		
Caucasian	86	78.2
Black	21	19.1
Other	3	2.7
Disease State		
OA	78	70.9
RA	32	29.1

APPEARS THIS WAY ON ORIGINAL

Population PK Model

Base Structural Model: One-compartment open model
Parameterized in terms of Ka, V/F and CL/F

Final PK model:
The final model is defined by the following equations:

$$k_{a_i} = \theta_1$$

$$V_i = \theta_2 e^{\eta_i^V}$$

$$Cl_i = \theta_3 \left(\theta_4^{x_i^{blk}}\right)\left(\theta_5^{x_i^{oth}}\right)\left(\frac{wt_i}{81.4kg}\right)^{\theta_6} e^{\eta_i^{Cl}}$$

APPEARS THIS WAY
ON ORIGINAL

where for the *ith* patient, x_i^{blk} and x_i^{oth} denote indicator variables for race (x_i^{blk} =1 if black, 0 otherwise and x_i^{oth} =1 if other noncaucasian and 0 otherwise) and wt_i denotes body weight. θ_1 and θ_2 denote the population mean parameters for k_a and V/F, respectively. θ_3 denotes the population mean Cl/F for caucasians with a body weight of 81.4 kg (median estimate from the 110 patients used in the data analysis). θ_4 and θ_5 denote the population mean parameters for the fractional change in Cl/F for blacks and other noncaucasians, respectively. θ_6 denotes the population mean exponent for body weight. η_i^V and η_i^{Cl} denote the interpatient random effects for V/F and Cl/F, respectively.

APPEARS THIS WAY
ON ORIGINAL

Population PK/PD Analysis

Table 1: Sample Size by Study and Dose

Study	Dose (mg)	PK Data		PD Data	
		Pts.	Obs.	Pts.	Obs.
005	0	n/a	n/a	50	108
	100	50	50	50	271
	400	50	50	50	264
025	0	n/a	n/a	50	303
	25	49	452	50	343
	50	50	526	50	415
	200	49	558	50	490
027	0	n/a	n/a	55	366
	100	54	686	55	540
	200	56	711	56	665
070	0	n/a	n/a	50	258
	50	34	423	35	264
	100	50	631	50	456
	200	50	626	50	471
	400	35	450	35	388
Totals		427[a]	5063[a]	736	5602[b]

a. Totals do not include the 005 study since a decision was made not to include 005 in the PK analysis due to the disparity in the amount of PK data per patient relative to the other studies.
b. Total corresponds to the number of observations prior to dropout.

PK Samples

Study -005: 1 hour postdose; data *excluded* from population PK analysis.

Studies -025, -027 and -070: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours postdose (no sampling after patients remedicated.)

PD Observations

PR score: 0: no pain relief 1: a little pain relief 2: some pain relief 3: a lot of pain relief 4: complete pain relief

Study -005: PR scores taken at 1, 1.5, 2, 3, 4, 5, 6, 7 and 8 hours postdose.

Studies -025, -027 and -070: PR scores determined at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 24 hours postdose.

APPEARS THIS WAY ON ORIGINAL

Table 2: A Comparison of Sponsor's and Reviewer's PK Models and Parameter Estimates

PK	Sponsor's Analysis	Reviewer's Analysis
Structural Model	1-compartment model Absorption lag time included. CL/F: same for all doses V_c/F: varied with dose $V_c/F = V_{c,pop}/F^* \times [Dose/100]^\gamma$	2-compartment model Absorption lag time included. CL & V_c: same for all doses but body weight as a covariate $CL = CL_{pop} \times [wt/66.8]^\gamma$ $V_c = V_{c,pop} \times [wt/66.8]^\gamma$ F and Ka: varied with dose
Parameter Estimates**		
Absorption Lag Time (hr)	0.398± 0.010 (69.2)	0.391 (31.6)
Ka (hr^{-1})	0.874 ± 0.053 (149)	0.697 (25 & 50 mg doses) (26.6) 0.538 (200 mg dose)
CL/F (L/hr) Body wt dependence factor, γ	35.6 ± 1.7 (55.8) -	18.3 (for body wt of 66.8 kg) (47.0) 1.70
V_c/F(L) Dose dependence factor, γ Body wt dependence factor, γ	283± 15 (100 mg dose) (57.3) 0.438 ± 0.047 -	87.3 (71.8) - 0.564
Q (L/hr)	-	41.5 (96.1)
V_p (L)	-	211 (98.7)
F'***	-	0.613 (25.4)

*$V_{c,pop}$: population mean for V_c; **Numbers in the parenthesis represent intersubject variability in %CV.
***F': bioavailability of 200 mg dose relative to the 25 mg & 50 mg doses

APPEARS THIS WAY
ON ORIGINAL

Table 3: A Comparison of Sponsor's and Reviewer's PD Models and Parameter Estimates

PD		Sponsor's Analysis	Reviewer's Analysis
Effect Compartment		Unnecessary (Keo very large)	Unnecessary (Keo very large)
Pain Relief Model	Placebo Effect	$f_p(m,t) = \Sigma\beta_k + p_1(1-e^{-\gamma t}) + p_2 \cdot t$	$f_p(m,t) = \Sigma\beta_k + p_1(1-e^{-\gamma t})$
	Drug Effect	Simple Emax model suffices: $f_d(C_p) = (E_{max} \cdot C_p)/(EC_{50} + C_p)$ Population mean C_p used	Simple Emax model suffices: $f_d(C_p) = (E_{max} \cdot C_p)/(EC_{50} + C_p)$ Individual C_p values used
	Time Effect on Intersub.Variability	$f_t(t) = t^{\chi}$	$f_t(t) = 1$
Remediation Model	Hazard Function	$\lambda(t \mid PR=m) = \Sigma\lambda_m (1+\theta (t-1)_+)$ $(t-1)_+ = t-1$ for $t \geq 1$ $(t-1)_+ = 0$ for $t < 1$	Same as sponsor's.
		Parameter Estimates	
Pain Relief	Baseline Increments		
	β_1	-2.48±0.25	-3.39±0.42
	β_2	-3.04± 0.12	-3.12±0.21
	β_3	-1.59±0.09	-1.52±0.19
	β_4	-3.40± 0.17	-2.60±0.26
	Placebo Effect		
	p_1	1.95±0.50	6.45±0.58
	p_2	0.153±0.029	-
	γ	1.03±0.20	0.447±0.100
	Drug Effect		
	EC_{50} (ng/mL)	501±192	465±265
	E_{max}	9.68±2.20	6.67±2.03
	Random Effect		
	Variance, ω^2	8.30±0.84	7.62±1.21
	Scaling factor, χ	0.240±0.041	-
Remediation (Hazard Function)	Baselines		
	λ_0	1.49±0.10	1.34±0.134
	λ_1	0.293±0.028	0.327±0.052
	λ_2	0.0288±0.0082	0.00479±0.0052
	λ_3	0.0126±0.0035	0.00301±0.00307
	λ_4	0.00253±0.00151	0.00299±0.00325
	Time Factor, θ	0.111±0.061	0.145±0.136

- Symbols related to placebo effect, $f_p(m,t)$:
  - β_k's : increments for baseline set of probabilities of the various degrees of pain relief
  - p_1, γ and p_2: parameters associated with the time varying nature of pacebo effect.
- Symbols related to drug effect, $f_d(C_p)$:
  - C_p : plasma celecoxib concentration; E_{max}: maximal drug effect;
  - EC_{50}: drug concenration corresponding to 50% of the maximum drug effect.
- Symbols related to random effect scaling function, $f_t(t)$:
  - χ: Scaling factor
- Symbols related to remediation model:
  - λ_0 - λ_4: baseline hazard for PR score of 0-4, respectively
  - θ: slope for time effect on hazard rate

Protocol No.: N49-98-02-084:

An Open Label, Randomized, Single Dose, Three-Way Crossover Study To Assess The Bioequivalency Of 100 MG And 200 MG SC-58635 In Healthy Adult Subjects

Study Dates: 2/20/98 - 3/30/98 *NDA Volume: 1.94-1.95*

Investigator/ Study Site	
Study Design	Open label, randomized, single-dose, three-way crossover
Subject Characteristics (*Healthy subjects*)	*No. of subjects* / *Age (yr)* / *Wt (kg)* / *Race* 53 (39M, 14F) / 33.6 ± 7.4 / 72.5± 10.3 / 11B, 5C, 37H 47 completed
Treatments (*Fasted*)	A: celecoxib 200 mg x 1 (commercial capsules; Lot # RCT 10720) B: celecoxib 100 mg x 2 (Phase III capsules; Lot #RCT 10718) C: celecoxib 100 mg x 2 (commercial capsules; Lot # RCT 10719) Dosing: Days 1, 8 and 15 (7-day washout); with 180 mL of water; 6 sequences
Sampling Scheme	*Blood:* 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hrs
Assay	*Blood samples (SC-58635):*
Adverse Events	Twelve subjects reported adverse events; none were considered to be related to the study drug. Clnical lab and vital signs: no clinically significant changes

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

!*** FINAL/LOCKED *** DISK$SEAR9724:[SEAR9724.LISTINGS]LDEMOG.SAS 28APR98 11:09

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.3
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	AGE (yrs)	DATE OF BIRTH	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US0001						
0001	23		MALE	BLACK		
0002	24		MALE	HISPANIC		
0003	44		MALE	HISPANIC		
0004	32		MALE	BLACK		
0005	27		MALE	CAUCASIAN		
0006	28		MALE	BLACK		
0007	35		MALE	HISPANIC		
0008	18		MALE	HISPANIC		
0009	28		MALE	HISPANIC		
0010	19		MALE	BLACK		
0011	29		MALE	HISPANIC		
0012	41		MALE	HISPANIC		
0013	42		MALE	HISPANIC		
0014	43		MALE	BLACK		
0015	43		MALE	HISPANIC		
0016	22		MALE	BLACK		

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.3
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	AGE (yrs)	DATE OF BIRTH	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US000.						
0017	37		MALE	HISPANIC		
0018	35		MALE	HISPANIC		
0019	22		MALE	HISPANIC		
0020	41		MALE	HISPANIC		
0021	34		MALE	HISPANIC		
0022	42		MALE	BLACK		
0023	28		MALE	CAUCASIAN		
0024	30		MALE	HISPANIC		
0025	40		MALE	HISPANIC		
0026	36		MALE	HISPANIC		
0027	41		MALE	HISPANIC		
0028	31		MALE	HISPANIC		
0029	37		MALE	HISPANIC		
0030	45		MALE	HISPANIC		
0031	43		MALE	HISPANIC		
0032	33		MALE	HISPANIC		

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.3
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	AGE (yrs)	DATE OF BIRTH	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US0001						
0033	37		MALE	CAUCASIAN		
0034	32		MALE	HISPANIC		
0035	29		MALE	HISPANIC		
0036	32		MALE	HISPANIC		
0037	30		MALE	HISPANIC		
0038	28		FEMALE	HISPANIC		
0039	29		FEMALE	CAUCASIAN		
0040	41		FEMALE	HISPANIC		
0041	38		FEMALE	CAUCASIAN		
0042	31		FEMALE	HISPANIC		
0043	41		FEMALE	BLACK		
0044	26		FEMALE	HISPANIC		
0045	43		FEMALE	HISPANIC		
0046	25		FEMALE	BLACK		
0047	30		FEMALE	BLACK		
0048	39		FEMALE	HISPANIC		

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.3
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	AGE (yrs)	DATE OF BIRTH	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US0001						
9002	43		MALE	BLACK		
9011	19		MALE	HISPANIC		
9034	36		FEMALE	HISPANIC		
9040	39		FEMALE	HISPANIC		
9042	39		FEMALE	HISPANIC		

APPEARS THIS WAY
ON ORIGINAL

171

BEST POSSIBLE COPY

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.7
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	PERIOD	TRT (a)	VISIT	AUC(0-48) (ng*hr/mL)	AUC(0-lqc) (ng*hr/mL)	AUC(0-inf) (ng*hr/mL)	Cmax (ng/mL)	Tmax (hr)	T(1/2) (hr)	RATE OF ABSORPTION (b) (1/hr)
<<< INVESTIGATIONAL UNIT CODE: US0001										
0027	1	A	DAY 01							
	2	B	DAY 08							
	3	C	DAY 15							
0028	1	B	DAY 01							
	2	C	DAY 08							
	3	A	DAY 15							
0029	1	B	DAY 01							
	2	C	DAY 08							
	3	A	DAY 15							
0030	1	C	DAY 01							
	2	A	DAY 08							
	3	B	DAY 15							
0031	1	A	DAY 01							
	2	C	DAY 08							
	3	B	DAY 15							
0032	1	A	DAY 01							
	2	B	DAY 08							
	3	C	DAY 15							
0033	1	B	DAY 01							
	2	A	DAY 08							
	3	C	DAY 15							
0035	1	C	DAY 01							
	2	A	DAY 08							
	3	B	DAY 15							

Notes:
(a) A = 1x200mg commercial capsule, B = 2x100mg Phase III capsule, C = 2x100mg commercial capsule.
(b) Rate of absorption = Cmax/AUC(0-lqc).

172

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.7
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	PERIOD	TRT (a)	VISIT	AUC(0-48) (ng*hr/mL)	AUC(0-lqc) (ng*hr/mL)	AUC(0-inf) (ng*hr/mL)	Cmax (ng/mL)	Tmax (hr)	T(1/2) (hr)	RATE OF ABSORPTION (b) (1/hr)
<<< INVESTIGATIONAL UNIT CODE: US0001										
0036	1	A	DAY 01							
	2	C	DAY 08							
	3	B	DAY 15							
0037	1	A	DAY 01							
	2	B	DAY 08							
	3	C	DAY 15							
0038	1	C	DAY 01							
	2	B	DAY 08							
	3	A	DAY 15							
0039	1	A	DAY 01							
	2	C	DAY 08							
	3	B	DAY 15							
0041	1	C	DAY 01							
	2	A	DAY 08							
	3	B	DAY 15							
0043	1	B	DAY 01							
	2	C	DAY 08							
	3	A	DAY 15							
0044	1	B	DAY 01							
	2	A	DAY 08							
	3	C	DAY 15							
0045	1	A	DAY 01							
	2	B	DAY 08							
	3	C	DAY 15							

Notes:
(a) A = 1x200mg commercial capsule, B = 2x100mg Phase III capsule, C = 2x100mg commercial capsule.
(b) Rate of absorption = Cmax/AUC(0-lqc).

173

BEST POSSIBLE COPY

!*** FINAL/LOCKED *** DISK$SEAR9724:[SEAR9724.LISTINGS]LPKPARM.SAS 28APR98 11:11 PAGE 6 OF 6

SC-58635 100 MG AND 200 MG CAPSULE BIOEQUIVALENCE STUDY
N49-98-02-084

APPENDIX 3.7
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	PERIOD	TRT (a)	VISIT	AUC(0-48) (ng*hr/mL)	AUC(0-lqc) (ng*hr/mL)	AUC(0-inf) (ng*hr/mL)	Cmax (ng/mL)	Tmax (hr)	T(1/2) (hr)	RATE OF ABSORPTION (b) (1/hr)
<<< INVESTIGATIONAL UNIT CODE: US0001										
0046	1	A	DAY 01							
	2	C	DAY 08							
	3	B	DAY 15							
0047	1	C	DAY 01							
	2	A	DAY 08							
	3	B	DAY 15							
0048	1	B	DAY 01							
	2	C	DAY 08							
	3	A	DAY 15							
9002	1	A	DAY 01							
	2	B	DAY 08							
	3	C	DAY 15							
9011	1	C	DAY 01							
	2	A	DAY 08							
	3	B	DAY 15							
9034	1	B	DAY 01							
	2	A	DAY 08							
	3	C	DAY 15							
9040	1	C	DAY 01							
	2	B	DAY 08							
	3	A	DAY 15							

Notes:
(a) A = 1x200mg commercial capsule, B = 2x100mg Phase III capsule, C = 2x100mg commercial capsule.
(b) Rate of absorption = Cmax/AUC(0-lqc).

Company Confidential - G.D. Searle & Co.

Protocol No.: N49-96-02-044:

An Open-Label, Randomized, Four Period, Two Treatment, Replicate Design Study To Evaluate The Comparative Bioavailability Of The Phase III And Commercial SC-58635 Capsule Formulations

Study Dates: 11/29/96 - 12/24/96 *NDA Volume: 1.96*

Investigator/ Study Site	
Study Design	Open label, randomized, four-period, two-treatment, single-dose, replicate design
Subject Characteristics (***Healthy subjects***)	*No. of subjects* 24 (14M, 10F); *Age (yr)* 33.3 ± 9.0; *Wt (kg)* 73.7± 11.7; *Race* 1B, 21C, 2H
Treatments ***(Fasted)***	A: celecoxib 200 mg (Lot # RCT 10290) B: celecoxib 200 mg (Lot # RCT 10291) Dosing: 200 mg with 180 mL of water; 7-day washout
Sampling Scheme	*Blood:* 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hrs
Assay	*Blood samples (SC-58635):* *Urine samoles (SC-58635 & SC-62807):*
Adverse Events	Clnical lab and vital signs: no clinically significant changes

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

! FINAL DEMO 05MAY97 10:40

SC-58635 COMPARATIVE BIOAVAILABILITY OF THE PHASE III AND COMMERCIAL CAPSULE FORMULATIONS
N49-96-02-044

APPENDIX 3.4
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	VISIT DATE	AGE (yrs)	DATE OF BIRTH	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US0001							
0001	29NOV1996	37		M	CAUCASIAN		
0002	29NOV1996	27		M	CAUCASIAN		
0003	29NOV1996	23		M	CAUCASIAN		
0004	29NOV1996	30		M	CAUCASIAN		
0005	29NOV1996	22		M	CAUCASIAN		
0006	29NOV1996	47		F	CAUCASIAN		
0007	29NOV1996	29		F	CAUCASIAN		
0008	29NOV1996	41		M	CAUCASIAN		
0009	29NOV1996	29		F	CAUCASIAN		
0010	29NOV1996	23		M	CAUCASIAN		
0011	29NOV1996	43		F	CAUCASIAN		
0012	29NOV1996	27		F	CAUCASIAN		
0013	29NOV1996	31		M	HISPANIC		
0014	29NOV1996	35		M	CAUCASIAN		
0015	29NOV1996	46		F	BLACK		
0016	29NOV1996	36		M	CAUCASIAN		
0017	29NOV1996	44		M	CAUCASIAN		
0018	29NOV1996	34		M	CAUCASIAN		

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

! FINAL DEMO 05MAY97 10:40 2

SC-58635 COMPARATIVE BIOAVAILABILITY OF THE PHASE III AND COMMERCIAL CAPSULE FORMULATIONS
N49-96-02-044

APPENDIX 3.4
LIST OF SUBJECT DEMOGRAPHICS

SUBJECT ID	VISIT DATE	AGE (yrs)	DATE OF BIRTH	SEX	RACE	HEIGHT (cm)	WEIGHT (kg)
<<< INVESTIGATIONAL UNIT CODE: US0001							
0019	29NOV1996	26		M	CAUCASIAN		
0020	29NOV1996	38		M	CAUCASIAN		
0021	29NOV1996	28		F	CAUCASIAN		
0022	29NOV1996	25		F	HISPANIC		
0023	29NOV1996	55		F	CAUCASIAN		
0024	29NOV1996	24		F	CAUCASIAN		

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

FINAL PKPARM1 05MAY97 10:41

SC-58635 COMPARATIVE BIOAVAILABILITY OF THE PHASE III AND COMMERCIAL CAPSULE FORMULATIONS
N49-96-02-044

APPENDIX 3.8
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	DAY	TREATMENT (a)	AUC (0-72) (ng/mL)*hr	Tmax (hr)	Cmax (ng/mL)	Terminal Half-life (hr)
<<< INVESTIGATIONAL UNIT CODE: US0001						
0001	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0002	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0003	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0004	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0005	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0006	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				

Note1: Pharmacokinetic parameters were not estimated for subject 0020 on day 15 (treatment = A) due to missing concentration data at 3 and 4 hours postdose.
Note2: Terminal Half-life was not estimable for subject 0022 on day 22 (treatment= A).
(a) A = 200 mg SC-58635
B = 200 mg SC-58635

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

178

Company Confidential - G.D. Searle & Co.

DRAFT

BEST POSSIBLE COPY

SC-58635 COMPARATIVE BIOAVAILABILITY OF THE PHASE III AND COMMERCIAL CAPSULE FORMULATIONS
N49-96-02-044

APPENDIX 3.8
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	DAY	TREATMENT (a)	AUC (0-72) (ng/mL)*hr	Tmax (hr)	Cmax (ng/mL)	Terminal Half-life (hr)
<<< INVESTIGATIONAL UNIT CODE: US0001						
0007	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0008	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0009	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0010	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0011	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0012	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				

APPEARS THIS WAY
ON ORIGINAL

Note1: Pharmacokinetic parameters were not estimated for subject 0020 on day 15 (treatment = A) due to missing concentration data at 3 and 4 hours postdose.
Note2: Terminal Half-life was not estimable for subject 0022 on day 22 (treatment=Formulation A).
(a) A = 200 mg SC-58635
B = 200 mg SC-58635

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

1 FINAL PKPARM1 05MAY97 10:41

SC-58635 COMPARATIVE BIOAVAILABILITY OF THE PHASE III AND COMMERCIAL CAPSULE FORMULATIONS
N49-96-02-044

APPENDIX 3.8
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	DAY	TREATMENT (a)	AUC (0-72) (ng/mL)*hr	Tmax (hr)	Cmax (ng/mL)	Terminal Half-life (hr)
<<< INVESTIGATIONAL UNIT CODE: US0001						
0013	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0014	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0015	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0016	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0017	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0018	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				

Note1: Pharmacokinetic parameters were not estimated for subject 0020 on day 15 (treatment = A) due to missing concentration data at 3 and 4 hours postdose.
Note2: Terminal Half-life was not estimable for subject 0022 on day 22 (treatment= A).
(a) A = 200 mg SC-58635
B = 200 mg SC-58635

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.

BEST POSSIBLE COPY

FINAL PKPARM1 05MAY97 10:41

SC-58635 COMPARATIVE BIOAVAILABILITY OF THE PHASE III AND COMMERCIAL CAPSULE FORMULATIONS
N49-96-02-044

APPENDIX 3.8
LIST OF SC-58635 PLASMA PHARMACOKINETIC PARAMETERS

SUBJECT ID	DAY	TREATMENT (a)	AUC (0-72) (ng/mL)*hr	Tmax (hr)	Cmax (ng/mL)	Terminal Half-life (hr)
<<< INVESTIGATIONAL UNIT CODE: US0001						
0019	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0020	DAY 1	B				
	DAY 8	A				
	DAY 22	B				
0021	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0022	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				
0023	DAY 1	B				
	DAY 8	A				
	DAY 15	A				
	DAY 22	B				
0024	DAY 1	A				
	DAY 8	B				
	DAY 15	B				
	DAY 22	A				

Note1: Pharmacokinetic parameters were not estimated for subject 0020 on day 15 (treatment = A)
due to missing concentration data at 3 and 4 hours postdose.
Note2: Terminal Half-life was not estimable for subject 0022 on day 22 (treatment= A).
(a) A = 200 mg SC-58635
B = 200 mg SC-58635

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Company Confidential - G.D. Searle & Co.